‘Remember her as the badass she was’: ALS patient who died should force Biogen, others to anticipate expanded access issues

It’s been two weeks since Lisa Stockman Mauriello passed away and a lingering question, in my mind, is whether she died in vain.

I’d like to think not.

During her final months, the 52-year-old former public relations executive battled Biogen, one of the world’s largest biotech companies, for access to an experimental treatment for ALS, a fatal neurological disease that gradually causes muscle weakness and paralysis.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In